Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Dermatologic drugs
Delgocitinib
Другие языки:

Delgocitinib

Подписчиков: 0, рейтинг: 0
Delgocitinib
Delgocitinib.svg
Clinical data
Trade names Corectim
Other names JTE-052; JTE-052A
ATC code
  • None
Legal status
Legal status
  • Rx-only in Japan
Identifiers
  • 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C16H18N6O
Molar mass 310.361 g·mol−1
3D model (JSmol)
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.


Новое сообщение